vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and STONERIDGE INC (SRI). Click either name above to swap in a different company.
STONERIDGE INC is the larger business by last-quarter revenue ($205.2M vs $183.1M, roughly 1.1× Amphastar Pharmaceuticals, Inc.). On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -6.0%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $2.6M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -7.4%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Stoneridge Inc is a global designer and manufacturer of advanced electrical and electronic components, integrated systems, and sensor solutions. It serves automotive, commercial vehicle, off-highway, and aerospace sectors, delivering products that boost vehicle safety, efficiency, connectivity, and environmental performance across key global markets.
AMPH vs SRI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $205.2M |
| Net Profit | $24.4M | — |
| Gross Margin | 46.8% | 16.2% |
| Operating Margin | 19.4% | -14.4% |
| Net Margin | 13.3% | — |
| Revenue YoY | -1.8% | -6.0% |
| Net Profit YoY | -35.7% | — |
| EPS (diluted) | $0.51 | $-2.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $205.2M | ||
| Q3 25 | $191.8M | $210.3M | ||
| Q2 25 | $174.4M | $228.0M | ||
| Q1 25 | $170.5M | $217.9M | ||
| Q4 24 | $186.5M | $218.2M | ||
| Q3 24 | $191.2M | $213.8M | ||
| Q2 24 | $182.4M | $237.1M | ||
| Q1 24 | $171.8M | $239.2M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $-9.4M | ||
| Q2 25 | $31.0M | $-9.4M | ||
| Q1 25 | $25.3M | $-7.2M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $-7.1M | ||
| Q2 24 | $37.9M | $2.8M | ||
| Q1 24 | $43.2M | $-6.1M |
| Q4 25 | 46.8% | 16.2% | ||
| Q3 25 | 51.4% | 20.3% | ||
| Q2 25 | 49.6% | 21.5% | ||
| Q1 25 | 50.0% | 21.2% | ||
| Q4 24 | 46.5% | 19.5% | ||
| Q3 24 | 53.3% | 20.8% | ||
| Q2 24 | 52.2% | 22.7% | ||
| Q1 24 | 52.4% | 20.2% |
| Q4 25 | 19.4% | -14.4% | ||
| Q3 25 | 13.2% | -1.6% | ||
| Q2 25 | 24.2% | -1.1% | ||
| Q1 25 | 21.9% | -1.5% | ||
| Q4 24 | 24.2% | -2.0% | ||
| Q3 24 | 29.8% | 0.1% | ||
| Q2 24 | 30.3% | 1.4% | ||
| Q1 24 | 27.9% | 0.1% |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | -4.5% | ||
| Q2 25 | 17.8% | -4.1% | ||
| Q1 25 | 14.8% | -3.3% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | -3.3% | ||
| Q2 24 | 20.8% | 1.2% | ||
| Q1 24 | 25.1% | -2.6% |
| Q4 25 | $0.51 | $-2.76 | ||
| Q3 25 | $0.37 | $-0.34 | ||
| Q2 25 | $0.64 | $-0.34 | ||
| Q1 25 | $0.51 | $-0.26 | ||
| Q4 24 | $0.74 | $-0.22 | ||
| Q3 24 | $0.78 | $-0.26 | ||
| Q2 24 | $0.73 | $0.10 | ||
| Q1 24 | $0.81 | $-0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $66.3M |
| Total DebtLower is stronger | $608.7M | $180.9M |
| Stockholders' EquityBook value | $788.8M | $179.8M |
| Total Assets | $1.6B | $551.2M |
| Debt / EquityLower = less leverage | 0.77× | 1.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $66.3M | ||
| Q3 25 | $276.2M | $54.0M | ||
| Q2 25 | $231.8M | $49.8M | ||
| Q1 25 | $236.9M | $79.1M | ||
| Q4 24 | $221.6M | $71.8M | ||
| Q3 24 | $250.5M | $54.1M | ||
| Q2 24 | $217.8M | $42.1M | ||
| Q1 24 | $289.6M | $48.4M |
| Q4 25 | $608.7M | $180.9M | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $201.6M | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $179.8M | ||
| Q3 25 | $776.7M | $251.2M | ||
| Q2 25 | $757.5M | $260.5M | ||
| Q1 25 | $751.3M | $253.1M | ||
| Q4 24 | $732.3M | $245.3M | ||
| Q3 24 | $727.7M | $271.4M | ||
| Q2 24 | $713.3M | $270.5M | ||
| Q1 24 | $672.4M | $277.3M |
| Q4 25 | $1.6B | $551.2M | ||
| Q3 25 | $1.7B | $632.1M | ||
| Q2 25 | $1.6B | $639.4M | ||
| Q1 25 | $1.6B | $657.4M | ||
| Q4 24 | $1.6B | $621.6M | ||
| Q3 24 | $1.5B | $662.5M | ||
| Q2 24 | $1.5B | $666.7M | ||
| Q1 24 | $1.6B | $675.4M |
| Q4 25 | 0.77× | 1.01× | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 0.82× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $8.8M |
| Free Cash FlowOCF − Capex | $24.6M | $2.6M |
| FCF MarginFCF / Revenue | 13.4% | 1.3% |
| Capex IntensityCapex / Revenue | 4.5% | 3.0% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $12.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $8.8M | ||
| Q3 25 | $52.6M | $3.6M | ||
| Q2 25 | $35.6M | $10.7M | ||
| Q1 25 | $35.1M | $10.9M | ||
| Q4 24 | $29.0M | $19.2M | ||
| Q3 24 | $60.0M | $10.8M | ||
| Q2 24 | $69.1M | $8.7M | ||
| Q1 24 | $55.3M | $9.1M |
| Q4 25 | $24.6M | $2.6M | ||
| Q3 25 | $47.2M | $-2.7M | ||
| Q2 25 | $25.0M | $7.4M | ||
| Q1 25 | $24.4M | $4.8M | ||
| Q4 24 | $16.6M | $14.0M | ||
| Q3 24 | $46.2M | $4.6M | ||
| Q2 24 | $63.1M | $1.5M | ||
| Q1 24 | $46.5M | $3.3M |
| Q4 25 | 13.4% | 1.3% | ||
| Q3 25 | 24.6% | -1.3% | ||
| Q2 25 | 14.3% | 3.3% | ||
| Q1 25 | 14.3% | 2.2% | ||
| Q4 24 | 8.9% | 6.4% | ||
| Q3 24 | 24.1% | 2.2% | ||
| Q2 24 | 34.6% | 0.6% | ||
| Q1 24 | 27.1% | 1.4% |
| Q4 25 | 4.5% | 3.0% | ||
| Q3 25 | 2.8% | 3.0% | ||
| Q2 25 | 6.1% | 1.4% | ||
| Q1 25 | 6.3% | 2.8% | ||
| Q4 24 | 6.7% | 2.4% | ||
| Q3 24 | 7.2% | 2.9% | ||
| Q2 24 | 3.3% | 3.0% | ||
| Q1 24 | 5.1% | 2.4% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | 3.11× | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
SRI
| Control Devices | $51.7M | 25% |
| Electronics | $38.0M | 19% |
| EE | $34.2M | 17% |
| SE | $28.6M | 14% |
| NL | $24.5M | 12% |
| Stoneridge Brazil | $14.1M | 7% |
| Asia Pacific | $13.1M | 6% |
